Molecular targeting therapy such as VEGF-tyrosine kinase inhibitors9 and mammalian target of rapamycin (mTOR) inhibitors 10,11 is used to treat advanced ccRCC and metastatic ccRCC patients. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.